Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WomanCare Global has taken over Roselle, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol, and Optinor, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel, from ICON.
Subscribe to our email newsletter
WomanCare Global said that both the products were developed by ICON in partnership with a trusted generic manufacturer following an extensive in-depth quality and technical assessment process undertaken by qualified experts in 2005.
With this acquisition, WomanCare Global has global rights to Roselle and Optinor and a partner in making these branded products available to IPPF’s global network of Member Associations located in over 170 countries.
WomanCare Global expects to market these products to other public and private sector markets around the world.
WomanCare Global chief operating officer Saundra Pelletier said that the addition of these 2 new products to their global portfolio will make a significant difference to women around the world who deserve access to high-quality and affordable products.
"Roselle and Optinor will become important options for women," Pelletier said.